181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)

作者：Peter Schmid, Sherene Loi, Luis de la Cruz‐Merino, R. Yerushalmi, S-A. Im, A. Sonnenblick, Maria Martinez‐García, Irene Moreno Candilejo, Liam Kennedy, Kristin Griffiths, Richard B. Schwab, Fiona Young, Linchuan Liao, Kelly DuPree, S-B. Kim · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103203 · 被引用次数：21 · 研究领域：HER2/EGFR in Cancer Research、Estrogen and related hormone effects、Cytokine Signaling Pathways and Interactions

Cancer immunotherapy has transformed the TNBC tx landscape but new combinations are needed to further improve survival outcomes. Atezo (PD-L1 inhibitor) + nab-paclitaxel (nab-P) is approved for first-line (1L) tx of PD-L1+, inoperable LA/mTNBC. SG (Trop-2-directed antibody–drug conjugate) is approved for 2L+ tx of mTNBC. We present the 18-week IA of the atezo + SG arm in MORPHEUS-panBC (NCT03424005).